Multicenter Phase 1/2a trial of CLN-081 (TAS6417) in NSCLC Patients with EGFR Exon 20 Insertion Mutations

Z. Piotrowska1, D. Planchard2, M. Clancy3, D. Witter3, L. Zawel1, H. Yu4
1Massachusetts General Hospital, Boston, MA USA, 2Gustave Roussy, Villejuif France, 3Cullinan Pearl Corp., Cambridge, MA USA, 4Memorial Sloan Kettering Cancer Center, New York, NY USA

Introduction
• Tyrosine kinase inhibitors [TKIs] targeting epidermal growth factor receptor (EGFR) mutations have been developed and approved as anticancer agents, but are largely ineffective against EGFR exon 20 insertion (Ex20ins) mutations.
  – Median overall survival for WT Ex20ins mutation patients is ~9 months in contrast to >40 months for sensitive EGFR mutations (e.g., Ex19del, L858R).
• There is a clinical need to develop novel EGFR TKIs targeting Ex20ins mutations while sparing wild type (WT) EGFR to simultaneously maximize efficacy and enhance the therapeutic window via reduction in WT EGFR driven toxicities.

Rationale
• While several novel agents targeting EGFR Ex20ins are in development, preliminary reports suggest that WT EGFR-related adverse events are common and may limit efficacy and durability of responses.
• CLN-081 is a potent inhibitor of Ex20ins mutations with a broad spectrum of EGFR mutant activity but also shows selectivity over WT EGFR suggesting a potentially wider clinical therapeutic window than most approved/in-development EGFR TKIs.

Study Objectives

<table>
<thead>
<tr>
<th>Phase 1</th>
<th>Phase 2a</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Primary</strong></td>
<td><strong>Primary</strong></td>
</tr>
<tr>
<td>Assess the safety and tolerability of orally administered CLN-081 monotherapy.</td>
<td>Evaluate the overall response rate (ORR). Define the Recommended Phase 2 dose (RP2D).</td>
</tr>
<tr>
<td>Define the maximum tolerated dose (MTD).</td>
<td>Evaluate duration of response (DOR), disease control rate (DCR), progression-free survival (PFS), survival rate, and OS.</td>
</tr>
<tr>
<td><strong>Secondary</strong></td>
<td><strong>Secondary</strong></td>
</tr>
<tr>
<td>To assess anti-tumor activity.</td>
<td>To compare the safety, tolerability and efficacy of twice daily (BID) dosing with the same total dose administered once daily (QD).</td>
</tr>
</tbody>
</table>

Exploratory
• To characterize select pharmacokinetics (PK) parameters. |
• To assess activity in patients with known central nervous system (CNS) disease.

Study Design
• This is an adaptive Ph1/2a trial evaluating CLN-081 in advanced NSCLC harboring Ex20ins mutations.
  – The trial consists of three parts: Ph1 Dose Escalation (Esc), Ph1 Dose Expansion (Exp), and Ph2a Dose Escalation (Dose Esc). Dose esc will be explored utilizing Accelerated Titration1 (AT) and Rolling Six+ (R6) designs.
  – Approximately 90 patients are planned. CLN-081 will be dosed continuously in 21-day cycles.
  – QD and BID dosing schedules will be explored.

Study Schema
• Dose esc will proceed initially according to AT design. The starting dose is 60 mg.
  – Conversion to R6 design is based upon pre-specified safety criteria.
  – Transition from part of the trial, Ph 1 dose escalation to dose expansion to Ph 2a, is based upon a Simon-Two Stage design.
  – Cohort expansion can occur at one or more doses:
    – Ph 1 exp based upon responses observed in Rolling Six cohorts.
    – Ph 2 exp based upon pre-specified response and safety criteria observed in Ph 1 dose exp.

Key Eligibility Criteria

<table>
<thead>
<tr>
<th>Inclusion Criteria</th>
<th>Exclusion Criteria</th>
</tr>
</thead>
<tbody>
<tr>
<td>No limit on prior EGFR TKIs, including prior EGFR Ex20 ins 20 inhibitors such as poziotinib, TAM-788, etc.</td>
<td>For All Cohorts</td>
</tr>
<tr>
<td>Limited prior exposure to EGFR TKIs (&gt; 6 mo of clinical benefit), including EGFR exon 20 inhibitors (&gt; 3 cycles with no progression)</td>
<td>Systemic anticancer treatment ≤ 14 days prior to CDDI</td>
</tr>
<tr>
<td>Age ≥ 18 and ECOG of 0 or 1</td>
<td>Limited field radiation ≤ 7 days or extended-field thoracic radiation ≤ 4 weeks</td>
</tr>
<tr>
<td>Measurable disease and lab parameters within normal limits</td>
<td>Major surgery ≤ 4 weeks</td>
</tr>
<tr>
<td>Brain metastases that are asymptomatic, treated, and stable ≤ 4 weeks</td>
<td>Mean resting QTc ≥ 470</td>
</tr>
</tbody>
</table>

CLN-081 Preclinical Data
• CLN-081 (formerly known as TAS6417) is a novel, orally available, broad spectrum EGFR inhibitor with activity against Ex20ins mutations.
  – Also active against exon19del, L858R, and T790M, as well as less common G719X, L861Q and S768I mutations.
• For Ex20ins mutations, selectivity indexes [WT EGFR/mutant EGFR ratio of inhibition] favored CLN-081 over poziotinib & osimertinib, suggestive of a wider therapeutic window.

Figure 1: Selectivity indexes - mutation selectivity calculated as ratios of IC50 values of Ba/F3 expressing WT EGFR to those of each of three cell line.

Figure 2: Selectivity indexes - Calculated as ratios of IC50 values of Ba/F3 expressing WT EGFR to those of each of three cell line.

Figure 3: CLN-081 is WT EGFR sparing. Inhibition of EGFR phosphorylation from H1975-insVSD (DTT) with no xenograft model in tumors (A) and in skin tissues (B).

Figure 4: CLN-081 vs poziotinib anti-tumor activity (A) and toxicity (B) in H1975-insVSD xenografts.

Figure 5: CLN-081 Study Design

Figure 6: CLN-081 Expansion to CDDI Schema

Poster presented at ICEG 2015, Barcelona, Spain, 6-10 March 2015
This trial is sponsored by Cullinan Pearl, Inc., a Cullinan Strategic Partne company. Cullinan Pearl Corp., Cambridge, MA USA. [Clinical Trials.gov Identifier: NCT04036682]
Correspondence to: Zbigniew Piotrowska E-mail: zpiotrowska@mgh.harvard.edu

References